Non-Cystic Fibrosis Bronchiectasis (NCFB) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: NA746E343157EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Non-Cystic Fibrosis Bronchiectasis (NCFB) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Non-Cystic Fibrosis Bronchiectasis (NCFB) Understanding

The DelveInsight Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology report gives a thorough understanding of the Non-Cystic Fibrosis Bronchiectasis (NCFB) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Non-Cystic Fibrosis Bronchiectasis (NCFB) in the US, Europe, and Japan. The report covers the detailed information of the Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology scenario in seven major countries (US, EU5, and Japan).

Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Perspective by DelveInsight

The Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Detailed Epidemiology Segmentation

The Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology covered in the report provides historical as well as forecasted Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Non-Cystic Fibrosis Bronchiectasis (NCFB) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Non-Cystic Fibrosis Bronchiectasis (NCFB) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Report and Model provide an overview of the global trends of Non-Cystic Fibrosis Bronchiectasis (NCFB) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Non-Cystic Fibrosis Bronchiectasis (NCFB) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Non-Cystic Fibrosis Bronchiectasis (NCFB)
• The report provides the segmentation of the Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology

Report Highlights

• 11-year Forecast of Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Non-Cystic Fibrosis Bronchiectasis (NCFB)
• Cases of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Mutation Types
• Non-Cystic Fibrosis Bronchiectasis (NCFB) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-Cystic Fibrosis Bronchiectasis (NCFB)?
• What are the key findings pertaining to the Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Non-Cystic Fibrosis Bronchiectasis (NCFB) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Non-Cystic Fibrosis Bronchiectasis (NCFB)?
• What are the currently available treatments of Non-Cystic Fibrosis Bronchiectasis (NCFB)?

Reasons to buy

The Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Non-Cystic Fibrosis Bronchiectasis (NCFB) market
• Quantify patient populations in the global Non-Cystic Fibrosis Bronchiectasis (NCFB) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutics in each of the markets covered
• Understand the magnitude of Non-Cystic Fibrosis Bronchiectasis (NCFB) population by its epidemiology
• The Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB)

3. NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment and Management
6.2. Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in 7MM (2019-2032)
Table 2: Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in the United States (2019-2032)
Table 4: Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in Germany (2019-2032)
Table 6: Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in France (2019-2032)
Table 8: Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in Italy (2019-2032)
Table 10: Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in Spain (2019-2032)
Table 12: Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in the United Kingdom (2019-2032)
Table 14: Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in Japan (2019-2032)
Table 16: Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in 7MM (2019-2032)
Figure 2 Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in the United States (2019-2032)
Figure 4 Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in Germany (2019-2032)
Figure 6 Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in France (2019-2032)
Figure 8 Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in Italy (2019-2032)
Figure 10 Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in Spain (2019-2032)
Figure 12 Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology in Japan (2019-2032)
Figure 16 Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report